Abivax to join cac mid 60 and sbf 120 indices following euronext paris annual review

Abivax to join cac mid 60 and sbf 120 indices following euronext paris annual review paris, france, september 12, 2025, 5:45 p.m. cest – abivax sa (euronext paris: fr0012333284 – abvx / nasdaq – abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today that following the annual review of the euronext paris indices on september 11, 2025, the scientific council of the indices has decided to admit abivax to the cac mid 60 and sbf 120 indices.
ABVX Ratings Summary
ABVX Quant Ranking